Bringing Life to PK Profiles

In Vivo-Relevance From an In Vitro Environment

Watch this webinar to learn:

• Introduce the working principles and flexibility of the PhysioMimix® PK
• Emphasize its capabilities regarding exposure to clinically relevant monotherapies or drug combinations/schedules
• Demonstrate the PhysioMimix® PK’s enhanced performance versus classical techniques

In this webinar, we introduce a new MPS platform designed to address these challenges: the PhysioMimix® PK – a novel microformulator developed by CN Bio. Professor John Wikswo invented the original unit from Vanderbilt University. By delivering dynamic, customized PK profiles for two drugs from human-relevant in vitro biological models, this unique technology provides a means to explore and predict clinically relevant treatment combinations and dosing schedules.

In drug development, microphysiological systems (MPS) are utilized to develop in vitro biological models that can generate more physiologically- and human-relevant data.

However, typical step-changes in drug concentrations from in vitro dosing solutions do not adequately reflect in vivo  pharmacokinetic (PK) exposure profiles, potentially resulting in an inaccurate ranking of drug effectiveness.

View our Q&A document from the live event.

Speaker Information:

Dr Tudor Petreus

Senior Scientist
CN Bio